Ironwood Pharmaceuticals | IRWD - Assets


Ironwood Pharmaceuticals reported $396.06M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.56B 233.42M Dec/2025
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Akebia Therapeutics USD 376.56M 12.41M Dec/2025
Almirall EUR 2.34B 29.21M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amarin USD 670.78M 10.96M Dec/2025
Ardelyx USD 501.6M 15.43M Dec/2025
Astellas Pharma JPY 3.6T 153.62B Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
Charles River Laboratories USD 7.14B 378.39M Dec/2025
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Emergent BioSolutions USD 1.82B 69.9M Dec/2023
Esperion Therapeutics USD 465.89M 101.87M Dec/2025
Halozyme Therapeutics USD 2.53B 304.09M Dec/2025
Incyte USD 6.96B 627.62M Dec/2025
Ironwood Pharmaceuticals USD 396.06M 53.12M Sep/2025
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
Lexicon Pharmaceuticals USD 184.99M 20.94M Dec/2025
MacroGenics USD 256.85M 13.92M Dec/2025
Moderna USD 12.34B 203M Dec/2025
Myriad Genetics USD 706.6M 21.5M Dec/2025
Pacira USD 1.26B 32.66M Dec/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
Takeda JPY 15.41T 938.47B Dec/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025